Ovarian cancer: screening, treatment, and follow-up

Article Abstract:

The National Institutes of Health's Consensus Development Panel on Ovarian Cancer provides guidelines for ovarian cancer screening, treatment, and patient follow-up. The panel reviewed scientific data and presented recommendations for ovarian cancer screening and management. Ovarian cancer screening should consist of a complete family medical history taking and a yearly rectovaginal pelvic examination. Patients with ovarian cancer should have careful surgical staging. Most women in the early stages of the disease will have their uterus, cervix, fallopian tubes, and ovaries surgically removed. This surgical approach plus chemotherapy is recommended for advanced ovarian cancer. Follow-up care for ovarian cancer patients who no longer have symptoms includes a medical history, physical examination, rectovaginal pelvic examination and CA-125 testing. Follow-up care for women who relapse is not curative and must emphasize patient quality of life.

Care and treatment, Reports, United States. National Institutes of Health, Ovarian cancer

---

A 35-year-old pregnant woman considering maternal serum screening and amniocentesis

Article Abstract:

Pregnant women over the age of 35 who want to take the triple screen to detect fetal abnormalities should receive extensive counseling. The triple screen involves measuring levels of alpha fetoprotein, human chorionic gonadotropin and unconjugated estriol in the woman's blood. The levels of these chemicals can indicate the presence of birth defects such as neural tube defects or Down syndrome. Many women have the triple screen to avoid having amniocentesis, which can be a risky procedure. They may also be reluctant to have a late-stage abortion if the amniocentesis reveals a genetic defect. However, a negative triple screen does not automatically rule out a genetic defect. Nor does a positive result automatically indicate a birth defect. The couple needs to weigh their risk of having a child with a major birth defect with the risks of losing the pregnancy following amniocentesis.

Planning, Diagnosis, Measurement, Birth defects, Amniocentesis, Chorionic gonadotropin, Chorionic gonadotropins, Alpha fetoproteins

---

Similar abstracts:

• Abstracts: Preemployment drug screening. Quality End-of-Life Care: Patients' Perspectives. Drug and neurotransmitter receptors: new perspectives with clinical relevance
• Abstracts: Valine, isoleucine, and leucine: a new treatment for phenylketonuria. The value of early treatment of deer tick bites for the prevention of Lyme disease
• Abstracts: Familial ovarian cancer in Israeli Jewish women. The management of pseudomyxoma peritonei
• Abstracts: Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro
• Abstracts: Efficacious treatments of PMS: a need for further research. Interventional radiological treatments tested. The Continuing Need for Late Abortions

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.